mProX™ Human CD86 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD86 is a protein that plays a role in various applications. In a study comparing the effects of lipid emulsions in human peripheral blood mononuclear cells (PBMCs), it was found that incubation with n-3 PUFA-rich lipid emulsion (Omegaven) led to an increase in CD86 expression in CD14+ monocytes. This increase in CD86 expression was associated with immunological synapse formation and an increase in IL-10 production, leading to a reduction in pro-inflammatory cytokines and an increase in T regulatory cells. Another study showed that targeting Tau-tubulin kinase 1 (TTBK1) with antisense oligonucleotides (ASOs) reduced the expression of phosphorylated tau in the hippocampus of PS19 tauopathy mice. CD86 was also found to be a potential biomarker of carotid atherosclerosis, with higher expression of CD86 associated with worse prognosis. Additionally, Toll-like receptor (TLR) agonists were found to affect the immunogenicity of MVA-SARS-2-S vaccine, with TLR3 agonist enhancing cellular immune responses. These findings suggest that CD86 and its modulation through various mechanisms have implications in inflammation, neurodegenerative diseases, atherosclerosis, and vaccine development.